Abstract
The review of articles devoted to the cost-effectiveness of percutaneous closure of the patent foramen ovale (PFO) from a taxpayer’s point of view has been conducted. A decrease in the incidence of recurrent ischaemic stroke is recorded in the correctly chosen patients after the percutaneous closure of the PFO. Patients with cryptogenic stroke associated with FPO are predominantly under the age of 60, that is, at the peak of economic performance and are vulnerable to long-term disability. To assess the cost-effectiveness of FPO closure in combination with different types of treatment, Markov’s models of patients with stroke in different studies, including six health conditions (stable post-stroke, transient ischaemic attack, post-transient ischaemic attack, clinical ischaemic stroke, post-clinical ischaemic stroke and death) were considered. Assessment of 5-year time horizon, costs and utility of FPO endovascular closure technology, incremental «cost-effectiveness» ratio (ICER) and total costs for quality-adjusted life year (QALY) has been conducted in comparison with medical treatment. Mechanisms and proposals for the use of appropriate models in the Russian patients’ population are outlined.

This publication has 26 references indexed in Scilit: